Paul青光眼植入物腔内ripcord缝线移除的结局
本研究为单中心回顾性队列研究,纳入2018年1月1日至2023年11月1日期间所有Paul青光眼植入物(PGI)ripcord缝线移除(ROS)病例,共145眼(131例患者)。主要终点为ROS后3个月眼压(IOP)降低≥20%或降眼压药物减少,70.3%的眼达到成功标准;第二管及鼻下象限管放置与成功率降低显著相关(p<0.05)。ROS后1周、1个月和3个月IOP及降眼压药物数均较ROS前显著降低(p<0.0001和p<0.005)。
要点
- ROS后3个月70.3%的眼达到主要终点(IOP降低≥20%或降眼压药物减少)。
- 第二管和鼻下管放置与ROS成功率降低显著相关(p<0.05)。
- 临床显著低眼压为最常见并发症(6.9%),其中4.1%需手术重新置入ripcord。
核心结论
- PGI的ROS使超过70%的眼达到IOP或降眼压药物至少20%的降低。
- 第二管和鼻下管放置与成功率降低相关。
- 临床低眼压是最常见并发症,与PGI植入后支架移除时间无关。
研究设计与样本
- 回顾性队列研究,纳入单中心2018年1月1日至2023年11月1日期间所有PGI ripcord移除病例,共145眼(131例患者)。
- 主要结局定义为ROS后3个月IOP降低≥20%或降眼压药物减少。
主要发现
- 70.3%的眼达到主要终点成功标准。
- 第二管和鼻下管放置与成功率降低显著相关(p<0.05)。
- ROS前平均IOP为19.5±6.7 mm Hg,ROS后1周、1个月和3个月分别显著降低至12.7±7.4 mm Hg、15.3±6.1 mm Hg和13.7±5.3 mm Hg(p<0.0001)。
- 降眼压药物数分别显著降低至0.44±0.97、0.75±1.18和1.12±1.30(p<0.005)。
- ROS后并发症包括临床显著低眼压(n=10,6.9%),其中6眼(4.1%)需手术重新置入ripcord;管分流阻塞(n=2,1.4%)和ROS后葡萄膜炎(n=1,0.69%)。
关键数值与推荐
- 主要终点成功标准:ROS后3个月IOP降低≥20%或降眼压药物减少。
- PGI植入至ROS的平均间隔为181.9±131.4天。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/AIMS: To investigate the efficacy and safety of intraluminal ripcord suture removal (ROS) from the Paul glaucoma implant (PGI). METHODS: A retrospective cohort study involving all PGI ripcord removal cases at a single centre between 1 January 2018 and 1 November 2023. The primary outcome was defined as a ≥20% reduction in intraocular pressure (IOP), or a decrease in IOP-lowering medications, at 3 months post-ROS. RESULTS: 145 eyes of 131 patients were included. The mean interval between PGI implantation and ROS was 181.9±131.4 days. 70.3% of eyes met the primary endpoint of success, with second tubes and infero-nasal tube placement significantly associated with reduced success (p<0.05). Compared with the pre-ROS mean IOP (19.5±6.7 mm Hg), the post-ROS IOPs at 1 week, 1 and 3 months were significantly reduced to 12.7±7.4 mm Hg, 15.3±6.1 mm Hg and 13.7±5.3 mm Hg, respectively (p<0.0001). Similarly, the number of IOP-lowering medications was significantly reduced to 0.44±0.97, 0.75±1.18 and 1.12±1.30, respectively (p<0.005). Post-ROS complications included clinically significant hypotony (n=10, 6.9%), of which 6 eyes (4.1%) required surgical ripcord re-insertion, tube shunt occlusion (n=2, 1.4%) and post-ROS uveitis (n=1, 0.69%). We found no predictive factors for post-ROS hypotony, including the time of ROS since PGI surgery. CONCLUSIONS: ROS from PGI resulted in at least 20% IOP or medication reduction in over 70% of eyes. Second and inferonasal tubes had reduced success. Clinical hypotony is the most common complication, without association with the time of stent removal since PGI implantation.
引用
- Mendel L, Tan JCK, Aguilar Munoa S, et al. Outcomes of intraluminal ripcord removal from Paul glaucoma implants. Br J Ophthalmol. 2025. PMID: 40588330. doi:10.1136/bjo-2024-326947
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。